Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
MDxHealth is a commercial-stage molecular diagnostics company focused on urologic cancers, primarily prostate cancer. The company's flagship products include SelectMDx (non-invasive urine test for prostate cancer risk stratification) and ConfirmMDx (epigenetic tissue test for ruling out repeat biopsies), marketed predominantly in the United States through a direct sales force and laboratory services model. With $100M revenue run-rate, 60% gross margins, and negative operating margins, MDXH is in the classic growth-stage diagnostic company profile: scaling commercial operations while burning cash to capture market share in the $2B+ prostate cancer testing market.
MDxHealth operates a CLIA-certified laboratory model where it processes proprietary molecular diagnostic tests ordered by urologists and primary care physicians. Revenue is generated per-test, with reimbursement from Medicare, commercial payers, and patient out-of-pocket payments. Average reimbursement rates range from $500-$1,500 per test depending on payer mix and test type. The company's competitive advantage lies in clinical validation data demonstrating negative predictive value >90% for SelectMDx, which helps urologists avoid unnecessary biopsies and reduce healthcare system costs. Pricing power is moderate, constrained by payer negotiations and competitive tests from Exact Sciences (Oncotype DX Prostate), Myriad Genetics, and emerging liquid biopsy platforms. The 60% gross margin reflects laboratory fixed costs, reagent expenses, and sample logistics, while negative operating margins stem from sales force expansion (50+ reps), clinical studies for label expansion, and reimbursement infrastructure investments.
Quarterly test volume growth rates and sequential acceleration (key indicator of commercial traction and urologist adoption)
Medicare and commercial payer reimbursement decisions, particularly CMS coverage determinations and LCD (Local Coverage Determination) updates for SelectMDx
Clinical data releases demonstrating improved outcomes or cost-effectiveness versus standard-of-care protocols (PSA testing, MRI, immediate biopsy)
Competitive developments from Exact Sciences, Myriad Genetics, or new entrants with prostate cancer liquid biopsy tests
Cash burn rate and runway visibility - company has historically required capital raises given negative FCF
Reimbursement compression risk as CMS and commercial payers scrutinize molecular diagnostic test pricing, particularly for tests with overlapping clinical utility. PAMA (Protecting Access to Medicare Act) mandates could reduce reimbursement rates 10-20% over multi-year periods.
Technological disruption from multi-cancer early detection (MCED) liquid biopsy platforms (Grail, Exact Sciences, Guardant Health) that could commoditize single-cancer focused tests and shift physician ordering patterns toward comprehensive screening panels
Clinical guideline changes - if NCCN or AUA guidelines shift toward MRI-first pathways or active surveillance protocols that reduce biopsy rates, demand for pre-biopsy risk stratification tests could decline
Exact Sciences' Oncotype DX Prostate test has stronger brand recognition and sales force scale (200+ reps vs MDXH's 50+), creating competitive pressure on urologist mindshare and test ordering patterns
Large diagnostics companies (Quest, LabCorp) developing in-house prostate cancer tests with bundled pricing advantages and existing physician relationships
Emerging AI-based imaging analysis tools that improve MRI accuracy could reduce need for molecular biomarker tests in risk stratification workflows
Negative equity position (ROE 517% with negative book value) indicates accumulated losses exceed assets, creating potential going concern risk if cash burn continues without revenue acceleration
Negative Debt/Equity ratio of -7.86 and current ratio of 1.08 suggest limited liquidity cushion - company likely needs to reach cash flow breakeven within 12-18 months or raise additional capital
Dilution risk from future equity raises given unprofitable operations and $200M market cap provides limited financing capacity without significant shareholder dilution
low - Prostate cancer screening and diagnostic testing is largely non-discretionary healthcare spending driven by clinical guidelines and physician referral patterns rather than consumer economic conditions. However, patient out-of-pocket costs for co-pays and deductibles can create modest sensitivity during recessions when high-deductible health plans cause patients to delay elective procedures. The company's revenue is more correlated with Medicare enrollment growth (aging demographics) and urology practice volumes than GDP cycles.
Moderate negative sensitivity through two channels: (1) Higher rates compress valuation multiples for unprofitable growth companies, as MDXH's negative earnings make it valued on forward revenue multiples (currently 1.6x P/S) which contract when discount rates rise. (2) Higher rates increase cost of capital for future equity or debt financing, which matters given the company's cash burn profile. Rising rates do not materially affect operating performance since the business has minimal debt ($0 capex suggests limited borrowing) and customer demand is rate-insensitive.
Minimal direct credit exposure. Revenue is primarily from government payers (Medicare/Medicaid) and large commercial insurers with low default risk. Accounts receivable risk is limited to patient responsibility portions and small urology practices. The company's own credit access matters more - tightening credit conditions could make future capital raises more dilutive or expensive if the company needs bridge financing before reaching cash flow breakeven.
growth/speculative - The stock attracts biotech/medtech growth investors willing to accept negative earnings and cash burn in exchange for potential 3-5x returns if the company captures 10-15% market share in prostate cancer diagnostics. The 120% one-year return followed by recent 9% pullback indicates momentum-driven trading with high retail participation. Not suitable for value or income investors given negative book value, no dividends, and binary outcome risk (either scales to profitability or requires dilutive financing).
high - Small-cap healthcare stocks with <$250M market cap, negative earnings, and binary clinical/reimbursement catalysts typically exhibit 40-60% annualized volatility. Stock price is highly sensitive to quarterly earnings beats/misses, reimbursement news, and competitive developments. Limited institutional ownership and low float amplify price swings on modest volume.
